Table 4.
Treatment response and changes of serum MPO–DNA of 29 patients with PsA.
| Items | Baseline | Week 12 | Week 24 |
|---|---|---|---|
| TJC | 3.0 (1.0, 8.0) | 3.0 (1.0, 5.0) | 2.0 (0.2, 3.7) |
| SJC | 2.0 (1.0, 6.0) | 2.0 (1.0, 3.0) | 1.0 (0, 3.0) |
| ESR, mm/h | 13.0 (7.7, 22.7) | 8 (4.0, 14.0) | 10 (2.0, 16.0) |
| CRP, mg/L | 3.0 (1.6, 11.8)† | 2.6 (1.3, 5.0) | 2.3 (1.0, 4.8) |
| PGA (0–100 mm) | 40 (20, 50)*†† | 20 (10, 40)†† | 10 (10, 27) |
| VAS-pain (0–100 mm) | 30 (10, 40)*†† | 20 (10, 30)†† | 10 (10, 20) |
| PASI | 2.8 (0.3, 6.5)*† | 0.7(0, 1.5) | 0.3 (0, 1.5) |
| DAPSA | 15 (8.3, 23.4)† | 8.4 (6.0, 14.4) | 6.1 (3.4, 13.7) |
| Serum MPO–DNA level | 0.416 (0.231, 0.846)* | 0.231 (0.153, 0.474) | – |
| Minimal disease activity, n (%) | 4 (13.7%) | 6 (20.6%) | 12 (41.3%) |
| ACR50, n (%) | – | 13 (44.8%) | 15 (51.7%) |
| PASI50, n (%) | – | 14 (48.2%) | 17 (58.6%) |
| ACR70, n (%) | – | 4 (13.7%) | 7 (24.1%) |
| PASI75, n (%) | – | 11 (37.9%) | 14 (48.2%) |
| ACR50/PASI50, n (%) | – | 8 (27.5%) | 13 (44.8%) |
| ACR70/PASI75, n (%) | – | 3 (10.3%) | 5 (17.2%) |
Values are presented as n (%) for binary variables or median (IQR) for continuous variables. TJC, tenderness joint count; SJC, swollen joint count; ESR, erythrocyte sediment rate; CRP, C-reactive protein; PGA, patient global assessment; EGA, examiner global assessment; DAPSA, disease activity in psoriatic arthritis score; ACR50/70, 50/70% improvement in terms of American College of Rheumatology response criteria; PASI50/75, 50/75% reduction in PASI score.
*Statistical significance at the level of 0.05 when compared with patients at week 12.
†Statistical significance at the level of 0.05 when compared with patients at week 24.
††Statistical significance at the level of 0.001 when compared with patients at week 24.